Aimmune Therapeutics (AIMT) Reports Q2 Loss of $0.43
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Join SI Premium – FREE
Aimmune Therapeutics (NASDAQ: AIMT) reported Q2 EPS of ($0.43), versus ($1.60) reported last year.
For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
